Wall Street analysts expect that Calithera Biosciences Inc (NASDAQ:CALA) will report ($0.24) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Calithera Biosciences’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.29). Calithera Biosciences reported earnings of ($0.45) per share in the same quarter last year, which would indicate a positive year over year growth rate of 46.7%. The firm is scheduled to issue its next earnings results on Thursday, March 15th.

On average, analysts expect that Calithera Biosciences will report full-year earnings of ($0.77) per share for the current fiscal year, with EPS estimates ranging from ($0.83) to ($0.73). For the next fiscal year, analysts expect that the business will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.98) to ($0.45). Zacks’ EPS averages are an average based on a survey of analysts that follow Calithera Biosciences.

Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $6.02 million.

CALA has been the subject of a number of research reports. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Monday, November 6th. William Blair initiated coverage on Calithera Biosciences in a research report on Thursday, October 5th. They set an “outperform” rating for the company. BidaskClub upgraded Calithera Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Finally, ValuEngine cut Calithera Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $15.17.

In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $15.64, for a total value of $9,008,640.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 16.30% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of CALA. State Street Corp increased its position in Calithera Biosciences by 5,802.1% in the second quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock worth $19,370,000 after buying an additional 1,282,275 shares in the last quarter. FMR LLC increased its position in Calithera Biosciences by 85.8% in the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock worth $40,349,000 after buying an additional 1,254,900 shares in the last quarter. Vanguard Group Inc. increased its position in Calithera Biosciences by 99.8% in the first quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock worth $10,684,000 after buying an additional 462,137 shares in the last quarter. Northern Trust Corp increased its position in Calithera Biosciences by 1,355.1% in the second quarter. Northern Trust Corp now owns 337,640 shares of the biotechnology company’s stock worth $5,014,000 after buying an additional 314,436 shares in the last quarter. Finally, American Century Companies Inc. increased its position in Calithera Biosciences by 272.8% in the third quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock worth $6,690,000 after buying an additional 310,806 shares in the last quarter. Institutional investors and hedge funds own 72.19% of the company’s stock.

Shares of Calithera Biosciences (NASDAQ CALA) opened at $8.90 on Wednesday. Calithera Biosciences has a 1 year low of $3.00 and a 1 year high of $20.05.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Calithera Biosciences Inc (CALA) to Post -$0.24 EPS” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/13/zacks-analysts-anticipate-calithera-biosciences-inc-cala-to-post-0-24-eps.html.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get a free copy of the Zacks research report on Calithera Biosciences (CALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.